<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82394">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030548</url>
  </required_header>
  <id_info>
    <org_study_id>NIS003684</org_study_id>
    <nct_id>NCT02030548</nct_id>
  </id_info>
  <brief_title>Bleeding in Patients Undergoing CABG During Dual Antiplatelet Therapy</brief_title>
  <official_title>Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate surgery-related bleeding and mortality in patients
      needing acute coronary artery bypass grafting with or without valve replacement during dual
      antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel,
      Ticagrelor)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>calculated blood loss</measure>
    <time_frame>until postoperative day 5</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>from index surgery until one year after index surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>acute CABG</arm_group_label>
    <description>patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients undergoing acute CABG with or without valve during dual antiplatelet
        therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        consecutive patients undergoing acute CABG with or without valve replacement within 48
        hours after last intake of dual antiplatelet therapy

        Exclusion Criteria:

        concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Mahla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Anesthesiology and Intensive Care Medicine, MUG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Mahla, MD</last_name>
    <phone>++43316385</phone>
    <phone_ext>13027</phone_ext>
    <email>elisabeth.mahla@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Pachler</last_name>
    <phone>++43316385</phone>
    <phone_ext>13027</phone_ext>
    <email>christoph.pachler@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Anesthesiology and Intensive Care Medicine</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Mahla, MD</last_name>
      <phone>++43316385</phone>
      <phone_ext>13027</phone_ext>
      <email>elisabeth.mahla@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Mahla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Pachler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Beran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Toller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
